Whole Person Healing.
For All.
Pioneering a New Era
in Modern Medicine
Expertise Informed by Experience
Sunstone is guided by a team of Clinical Research Coordinators with over 30 years of combined clinical expertise and over 5 years of specialized experience in psychedelic research.
We are currently offering trials to address depression, treatment-resistant depression, postpartum depression, cancer and depression, adjustment disorder, and PTSD. These trials use a variety of psychedelic compounds including, but not limited to psilocybin, MDMA, and 5-MeO-DMT.
Explore Open Studies- Adjustment Disorder (AD)
- Palliative Care
- Generalized Anxiety Disorde
- Major Depressive Disorder (MDD)
- MDD and Cancer
- Post-Traumatic Stress Disorder
- Postpartum Depression
- Treatment-Resistant Depression
- Psilocybin
- MDMA
- LSD
- 5-MeO-DMT
- Methylone
- RE-104 (novel serotonergic antidepressant)
- Beckley Psytech
- Compass Pathways
- Cybin
- Lykos Therapeutics
- MindMed
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic &
- Consciousness Research
- McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Participating in a clinical trial at Sunstone contributes to advancing scientific knowledge in the field of mental health research. Sunstone’s clinical team has authored [11] papers on psychedelic research in leading journals, including Cancer, JAMA Oncology, and NIH-Heals.
View Published Research